Rodrigo Gularte-Mérida

Supplementary Table S5. Transcriptome-wide differential gene expression between cluster 8 of P12 vs. all other P12 clusters.

Clinical trial design and efficacy. A, Study schema depicting treatment and biopsy collection time points. B, Flow diagram of treatment and follow-up for patients in the safety lead-in and trial expansion cohorts. C, Waterfall plot showing best percent tumor volume change from baseline per RECIST 1.1. One patient who was not evaluable for response by RECIST 1.1 is excluded. irAE(+), solid circles indicate irAEs; SC+, single-cell data from tumor biopsies, in which filling of the left and right halves indicates analyzability at the pre- and post-retifanlimab time points, respectively. D, Spider plot showing percent change in sum of target lesion diameters over time in patients who were evaluable for response by RECIST v1.1. E, Swimmer plot showing patient PFS. Dashed line indicates median PFS. NE, not evaluable; OR, overall response.

Changes in proportions of T-cell populations with anti–PD-1 via high-parameter flow cytometry. A, Change in abundance of T-cell subtypes with initiation of retifanlimab in patients with paired biopsies and detectable tumor-infiltrating T cells. B, Boxplot depicting percent change post- vs. pre-retifanlimab in the abundance of 63 T cell types. Filled boxes with bold labels and asterisks indicate T cell subsets with significant changes (P < 0.05; FDR < 0.05). C and D, Percent change in four key subsets of (C) CD4+ and (D) CD8+ T cells. OR, overall response.

Supplementary Figure S1. Survival. A) Kaplan-Meier curve for progression-free survival. B) Kaplan-Meier curve for overall survival.

Table 1 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma

Supplementary Table S3. Representativeness of Study Participants

Supplementary Figure S2. Classification of cancer cells according to WD/DD liposarcoma signatures.

Supplementary Table S1. Flow cytometry antibodies.

TRAEs occurring in ≥10% of patients.

Changes in tumor and immune cell populations and phenotypes with anti–PD-1. A,CDK4 and MDM2 expression in tumor cells according to best response. PD, P03, before and after retifanlimab initiation (IO); SD, three before IO and six after IO. B, Signature scores in tumor cells according to best response. Same samples as in A. C, Integrated clustering of cancer cells from patients with paired samples and sufficient tumor fraction. D and E, Intracluster signature score changes with initiation of retifanlimab, plotted (D) along the x-axis or (E) as dot size. F, Volcano plot of differential expression of genes related to immune response in cluster 8 vs. all other clusters from P12.